

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2013

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F      FORM 40-F \_\_\_\_\_

  X  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: June 25, 2013

By: /s/ "Scott Davis"  
Scott Davis  
Chief Financial Officer

**Exhibits:**

99.1 News Release dated June 21, 2013

## **Stellar Biotechnologies Announces Resignation of Board Member**

**Port Hueneme, CA (June 21, 2013) Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (OTCQB: SBOTF) (TSX-V: KLH)** announced that Darrell Brookstein has resigned from his role as Executive VP, Corporate Development and Finance, and from his positions on the Company’s Board of Directors, effective June 21, 2013.

Mr. Brookstein has served on the Board since April 2010. He is resigning to devote more time to personal and outside business commitments.

“Stellar is a great company with very attractive growth potential,” said Mr. Brookstein. “I believe the path laid out for the Company’s future is well thought out and contains the seeds for greater success. I am very confident in the Company’s prospects and I remain supportive of its progress, and the Board’s good efforts, in any way possible.”

Frank Oakes, Stellar Chairman said: “On behalf of the Board, we want to thank Darrell for his contributions as Executive VP and a Director of the Company. Darrell was instrumental in the Company’s early structuring and its transformation into a publicly-held corporation. We appreciate his thoughtful input to Stellar’s business strategy and his passion for our technology. We wish Darrell well in his future activities.”

### **About Stellar Biotechnologies, Inc.**

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX-V: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of [http://stellarbiotechnologies.com/investors/news\\_releases/](http://stellarbiotechnologies.com/investors/news_releases/).

Visit [www.StellarBiotech.com](http://www.StellarBiotech.com) and [www.KLHsite.com](http://www.KLHsite.com).

### **Contact**

Frank Oakes, Chairman

Phone: +1 (805) 488-2800

Email: [InvestorRelations@stellarbiotech.com](mailto:InvestorRelations@stellarbiotech.com)

### **Investor Relations**

MZ Group

Mark A. McPartland

Senior Vice President

Phone: +1 (212) 301-7130

Email: [markmcp@mzgroup.us](mailto:markmcp@mzgroup.us)

Web: [www.mzgroup.us](http://www.mzgroup.us)

### **Forward Looking Statements**

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.